Table of Contents Table of Contents
Previous Page  300 / 398 Next Page
Information
Show Menu
Previous Page 300 / 398 Next Page
Page Background

295

Malignant myoepithelioma arising in the soft palate – report

of a case

S. Suzuki

∗

, T. Sano, T. Kijima, T. Akimoto, S. Kubodera,

H. Ubukata, T. Hagino, K. Sudo, Y. Sato, S. Takaku

Department of Oral and Maxillofacial Surgery, Tokyo Nishi

Tokushukai Hospital, Japan

Background:

Malignant myoepithelioma (MM) is a rare salivary

gland neoplasm. It was first treated as an independent disease

entity in theWHO classification of salivary gland tumours in 1991.

It is a rare tumour accounting for less than 1% of salivary gland

neoplasm.

Objectives:

We present a case of MM in the soft palate and discuss

its therapeutic aspect.

Case Report:

A 76-year-old man was referred to our hospital for

evaluation of a swelling in the left soft palate, which he had been

aware of for 15 years. Recently he complained of disturbance

of swallowing. Computed tomography and magnetic resonance

imaging showed a 40 mm-in-diameter, mixed density mass in the

left palate with no obvious lymph node enlargement. Surgical

resection of the tumour was performed. Since it was diagnosed

as MM, he underwent postoperative chemoradiation. The patient

has done well with no sign of recurrence for four years.

Findings and Conclusion:

Microscopically, increase of spindle-

shaped cells and the plasmacytoid-cells were recognised in the

mucinous stroma in haematoxylin and eosin staining. In immuno-

histochemical staining, keratin 15 was positive in neoplastic cells.

In addition, the positive rate of Ki 67 was around 5%. Also, inva-

sion to capsule was observed. So it was diagnosed as MM. As

for treatment of MM, there have been a few reports and surgical

resection is the mainstay of therapy. Postoperative chemoradia-

tion is highly recommended in the case like ours, where the tumour

could not be resectedwith enough surgical margin not for technical

but for anatomical reason.

http://dx.doi.org/10.1016/j.ijom.2017.02.992

Minimising postoperative pain after head and neck surgery –

the use of ultrasound guided superficial cervical plexus nerve

block immediately prior to surgery

A. Tahim

∗

, L. Cheng, A. Jones, C. Grant, S. Ali, J. Blanchard,

L. Johnston, C. Schwiebert

St Bartholomew’s, The Royal London and Homerton University

Hospitals, United Kingdom

Background:

Controlling operative pain is vital in ensuring a

comfortable and successful recovery after head and neck surgery.

The superficial cervical plexus block has been used in vascular

and thyroid surgery to reduce postoperative pain and minimise

analgesic requirement. We present our series of head and neck

patients who received this nerve block, and its effect on pain and

analgesic needs.

Methods:

A retrospective case note review was carried out for all

patients who received ultrasound guided cervical plexus blocks

prior to their procedure. Basic demographic data, nature of surgery

and intraoperative analgesia were recorded. Postoperative visual

analogue scores were noted, as was analgesia requirements and

complications.

Results:

54 patients received blocks under ultrasound guidance of

typically 10 mL of 0.5% levobupivicaine for a range of procedures

including thyroid and parathyroid surgery, neck dissections and

branchial cyst, lymph nodes and submandibular gland excision.

Intraoperative analgesia involved paracetamol, non-steroidal anti-

inflammatory drugs (NSAIDS) and stronger opioids in most cases.

96.2% and 72.2% patients used regular paracetamol and NSAIDS

postoperatively with 40.7% making use of opioid analgesia as

required. The majority of patients report pain scores between 1

and 3 postoperatively although 7.4% reported significant pain.

1.9% suffered a transient inadvertent brachial plexus block, which

resolved during the follow-up period.

Conclusion:

The ultrasound guided superficial cervical plexus

block is a useful tool in a surgeon’s armamentarium prior to head

and neck surgery. Our series demonstrates that it is well tolerated

and can be used effectively in a range of oral, maxillofacial, head

and neck surgical procedures.

http://dx.doi.org/10.1016/j.ijom.2017.02.993

Neutron radiation efficacy when treating salivary gland

malignancies

M. Timoshchuk

∗

, P. Dekker, C. Davis, G. Laramore, J. Dillon

University of Washington School of Dentistry, United States

Background:

There is limited literature regarding oral complica-

tions following neutron radiotherapy (NRT)

. 1

Objectives:

The aimof this followup studywas to estimate: (1) the

rates of locoregional control and (2) the frequency of oral compli-

cations in subjects with head and neck salivary gland malignancies

treated with NRT.

Methods:

This is a retrospective case series of patients with

salivary gland malignancies treated with NRT by the Radiation

Oncology Department at the UW from 1997 to 2010. Study vari-

ables were demographic, surgical, pathological, radiologic, etc.

Univariate statistics were computed for each study variable and

Kaplan–Meier methods were used to estimate locoregional recur-

rence.

Findings:

The sample was composed of 562 patients with a mean

age of 54.1 years (standard deviation, 15.9 years). 48% were

male. Adenoid cystic carcinoma (47.1%) and parotid location

(55.8%) predominated. Perineural and lymphatic invasion was

present in 49% and 26% of subjects, respectively. The six-year

locoregional control rate was 70%. Mucositis, xerostomia, and

osteoradionecrosis occurred in 81, 83, and 5.1% of subjects.

Conclusion:

The locoregional control rate of 70% compares

favourably to the rate reported in the literature for photon radiation

treatment of the same areas. The frequency of ORN was compa-

rable to photon radiation treatment of the same areas (4–7%).

Given the potential benefits of NRT, dental professionals should

be educated regarding its indications and oral complications.

Reference

1. Davis, C., Sikes, J., Namaranian, P., Laramore, G., & Dillon, J. K. (2016).

Neutron beam radiation therapy: an overview of treatment and oral com-

plications when treating salivary gland malignancies.

J Oral Maxillofac

Surg

,

74

, 830–835.

http://dx.doi.org/10.1016/j.ijom.2017.02.994